"Trans-Activators" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Diffusible gene products that act on homologous or heterologous molecules of viral or cellular DNA to regulate the expression of proteins.
| Descriptor ID |
D015534
|
| MeSH Number(s) |
D12.776.260.755 D12.776.930.900 D12.776.964.925.984
|
| Concept/Terms |
Trans-Activators- Trans-Activators
- Trans Activators
- Transactivators
- Trans-Activator
- Trans Activator
- Transactivator
- Trans-Acting Factor
- Factor, Trans-Acting
- Trans Acting Factor
- Trans-Acting Factors
- Factors, Trans-Acting
- Trans Acting Factors
Nuclear Trans-Acting Factor- Nuclear Trans-Acting Factor
- Factor, Nuclear Trans-Acting
- Nuclear Trans Acting Factor
- Trans-Acting Factor, Nuclear
|
Below are MeSH descriptors whose meaning is more general than "Trans-Activators".
Below are MeSH descriptors whose meaning is more specific than "Trans-Activators".
This graph shows the total number of publications written about "Trans-Activators" by people in this website by year, and whether "Trans-Activators" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 1 | 2 |
| 1999 | 2 | 0 | 2 |
| 2000 | 3 | 0 | 3 |
| 2001 | 1 | 0 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 2 | 0 | 2 |
| 2007 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2014 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Trans-Activators" by people in Profiles.
-
The Epigenetic Modulation of Cancer and Immune Pathways in Hepatitis B Virus-Associated Hepatocellular Carcinoma: The Influence of HBx and miRNA Dysregulation. Front Immunol. 2021; 12:661204.
-
The Multiple Roles of Hepatitis B Virus X Protein (HBx) Dysregulated MicroRNA in Hepatitis B Virus-Associated Hepatocellular Carcinoma (HBV-HCC) and Immune Pathways. Viruses. 2020 07 10; 12(7).
-
Sustained inhibition of hepatitis B virus replication in vivo using RNAi-activating lentiviruses. Gene Ther. 2015 Feb; 22(2):163-71.
-
Impact of sustained RNAi-mediated suppression of cellular cofactor Tat-SF1 on HIV-1 replication in CD4+ T cells. Virol J. 2012 Nov 15; 9:272.
-
Increased expression of ErbB-2 in liver is associated with hepatitis B x antigen and shorter survival in patients with liver cancer. Int J Cancer. 2009 Oct 15; 125(8):1894-901.
-
Hepatitis B x antigen up-regulates vascular endothelial growth factor receptor 3 in hepatocarcinogenesis. Hepatology. 2007 Jun; 45(6):1390-9.
-
Enhanced cell survival of Hep3B cells by the hepatitis B x antigen effector, URG11, is associated with upregulation of beta-catenin. Hepatology. 2006 Mar; 43(3):415-24.
-
Downregulation of E-cadherin by hepatitis B virus X antigen in hepatocellullar carcinoma. Oncogene. 2006 Feb 16; 25(7):1008-17.
-
Effective inhibition of HBV replication in vivo by anti-HBx short hairpin RNAs. Mol Ther. 2006 Feb; 13(2):411-21.
-
Human S15a expression is upregulated by hepatitis B virus X protein. Mol Carcinog. 2004 May; 40(1):34-46.